EuroAPI Header EuroAPI Header

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Knight Therapeutics","sponsor":"Debiopharm","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Knight Partners With Debiopharm for the Commercialization of Trelstar\u00ae in Canada","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"January 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Approved"},{"orgOrder":0,"company":"Knight Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Knight and TherapeuticsMD Announce Health Canada Approval of IMVEXXY\u00ae","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"August 2020","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved"},{"orgOrder":0,"company":"Knight Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Knight Therapeutics Announces Filling of Supplement to a New Drug Submission for NERLYNX\u00ae to Treat HER2-Positive Metastatic Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"September 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Approved"},{"orgOrder":0,"company":"Knight Therapeutics","sponsor":"TherapeuticsMD","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Knight and TherapeuticsMD Announce Health Canada Approval of BIJUVA\u00ae","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"September 2020","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved"},{"orgOrder":0,"company":"Knight Therapeutics","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","amount":"$180.0 million","upfrontCash":"$168.0 million","newsHeadline":"Knight Therapeutics to Acquire Regional Rights to Exelon\u00ae","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"April 2021","url1":"","url2":"","graph1":"Neurology","graph2":"Approved"},{"orgOrder":0,"company":"Knight Therapeutics","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","amount":"$180.0 million","upfrontCash":"$168.0 million","newsHeadline":"Knight Therapeutics Announces Closing of Previously Announced Acquisition and Exclusive License to Exelon\u00ae in Canada and Latin America","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"May 2021","url1":"","url2":"","graph1":"Neurology","graph2":"Approved"},{"orgOrder":0,"company":"Knight Therapeutics","sponsor":"Profounda Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Grants Profounda Orphan Drug Designation Approval for treatment of Treatment of Invasive Candidiasis with Miltefosine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"November 2021","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed"},{"orgOrder":0,"company":"Knight Therapeutics","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Knight Therapeutics Assumes Commercial Activities and Re-Launches Exelon in Brazil","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"August 2022","url1":"","url2":"","graph1":"Neurology","graph2":"Approved"},{"orgOrder":0,"company":"Knight Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Knight Therapeutics Assumes Commercial Activities and Re-Launches Exelon in Brazil","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"August 2022","url1":"","url2":"","graph1":"Neurology","graph2":"Approved"},{"orgOrder":0,"company":"Knight Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Knight Therapeutics Assumes Commercial Activities for Exelon in Colombia","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"June 2022","url1":"","url2":"","graph1":"Neurology","graph2":"Approved"},{"orgOrder":0,"company":"Knight Therapeutics","sponsor":"Basilea Pharmaceutica","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$11.2 million","newsHeadline":"Cresemba\u00ae Sales in Latin America Trigger First Sales Milestone Payment to Basilea","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"January 2024","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved"}]

    Find Clinical Drug Pipeline Developments & Deals by Knight Therapeutics

    Menu

    Knight Therapeutics

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    DOSSIERs // Finished Dosage Forms

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Knight Therapeutics

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Canada
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Cresemba® Sales in Latin America Trigger First Sales Milestone Payment to Basilea

              Details:

              Under the licensing agreement, Knight will focus on the Cresemba (isavuconazole sulfate) to commercialize in Latin America. It is an approved azole antifungal product indicated for the treatment of adult patients with invasive aspergillosis.

              Lead Product(s): Isavuconazonium Sulfate

              Therapeutic Area: Infections and Infectious Diseases Product Name: Cresemba

              Highest Development Status: Approved Product Type: Small molecule

              Recipient: Basilea Pharmaceutica

              Deal Size: Undisclosed Upfront Cash: $11.2 million

              Deal Type: Licensing Agreement January 19, 2024

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Knight Therapeutics

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Canada
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Knight Therapeutics Assumes Commercial Activities and Re-Launches Exelon in Brazil

              Details:

              Exelon Patch (rivastigmine transdermal system) is a class of medications called cholinesterase inhibitors, which is used to manage and treat neurodegenerative disease, specifically dementia, in patients with Alzheimer and Parkinson disease.

              Lead Product(s): Rivastigmine

              Therapeutic Area: Neurology Product Name: Exelon

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Novartis Pharmaceuticals Corporation

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable August 15, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Knight Therapeutics

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Canada
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Knight Therapeutics Assumes Commercial Activities and Re-Launches Exelon in Brazil

              Details:

              Exelon (rivastigmine tartrate) is an oral acetylcholinesterase inhibitor, which is approved for the treatment of mild to moderately severe dementia in people with Alzheimer's disease and Parkinson's disease..

              Lead Product(s): Rivastigmine Tartrate

              Therapeutic Area: Neurology Product Name: Exelon

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable August 15, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Knight Therapeutics

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Canada
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Knight Therapeutics Assumes Commercial Activities for Exelon in Colombia

              Details:

              Exelon (rivastigmine tartrate) is an oral acetylcholinesterase inhibitor, which is approved for the treatment of mild to moderately severe dementia in people with Alzheimer's disease and Parkinson's disease..

              Lead Product(s): Rivastigmine Tartrate

              Therapeutic Area: Neurology Product Name: Exelon

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable June 01, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Knight Therapeutics

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Canada
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              FDA Grants Profounda Orphan Drug Designation Approval for treatment of Treatment of Invasive Candidiasis with Miltefosine

              Details:

              Miltefosine is an alkyllysophospholipid analogue drug with in vitro activity against the promastigote and amastigote stages of Leishmania species. Leishmaniasis is a parasitic disease that is found in parts of the tropics, subtropics, and southern Europe.

              Lead Product(s): Miltefosine

              Therapeutic Area: Infections and Infectious Diseases Product Name: Impavido

              Highest Development Status: Undisclosed Product Type: Small molecule

              Recipient: Profounda Pharmaceuticals

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable November 08, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Knight Therapeutics

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Canada
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Knight Therapeutics Announces Closing of Previously Announced Acquisition and Exclusive License to Exelon® in Canada and Latin America

              Details:

              Knight Therapeutics has acquired exclusive rights to manufacture, market and sell Exelon® (rivastigmine Patch, Capsules and Solution) in Canada and Latin America, as well as an exclusive license to use the intellectual property and the Exelon trademark, from Novartis.

              Lead Product(s): Rivastigmine Tartrate

              Therapeutic Area: Neurology Product Name: Exelon

              Highest Development Status: Approved Product Type: Small molecule

              Recipient: Novartis Pharmaceuticals Corporation

              Deal Size: $180.0 million Upfront Cash: $168.0 million

              Deal Type: Acquisition May 26, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Knight Therapeutics

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Canada
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Knight Therapeutics to Acquire Regional Rights to Exelon®

              Details:

              Exelon (rivastigmine) is a prescription product that was first approved in 1997 and is currently registered and sold in approximately 90 countries. Exelon is indicated for the symptomatic treatment of mild to moderately severe dementia in people with Alzheimer's disease.

              Lead Product(s): Rivastigmine Tartrate

              Therapeutic Area: Neurology Product Name: Exelon

              Highest Development Status: Approved Product Type: Small molecule

              Recipient: Novartis Pharmaceuticals Corporation

              Deal Size: $180.0 million Upfront Cash: $168.0 million

              Deal Type: Acquisition April 23, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Knight Therapeutics

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Canada
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Knight and TherapeuticsMD Announce Health Canada Approval of BIJUVA®

              Details:

              BIJUVA is a once-daily combination of estradiol and progesterone in a single oral capsule that will be available in two strengths in Canada indicated for the treatment of moderate to severe vasomotor symptoms associated with menopause in women with an intact uterus.

              Lead Product(s): Estradiol,Progesterone

              Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: Bijuva

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: TherapeuticsMD

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable September 21, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Knight Therapeutics

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Canada
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Knight Therapeutics Announces Filling of Supplement to a New Drug Submission for NERLYNX® to Treat HER2-Positive Metastatic Breast Cancer

              Details:

              The SNDS is supported by the results of the Phase IIINALA trial, a randomized controlled trial of neratinib plus capecitabine versus Tykerb® (lapatinib) plus capecitabine in HER2-positive metastatic breast cancer patients previously treated with = 2 HER2-directed regimens.

              Lead Product(s): Neratinib,Capecitabine

              Therapeutic Area: Oncology Product Name: Nerlynx

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable September 03, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Knight Therapeutics

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Canada
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Knight and TherapeuticsMD Announce Health Canada Approval of IMVEXXY®

              Details:

              In Canada, IMVEXXY is approved for the treatment of postmenopausal moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy (VVA).

              Lead Product(s): Estradiol

              Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: Imvexxy

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable August 25, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              With Fermion, start the journey of your innovative API.
              Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients & provides custom-made solutions.
              Post Enquiry
              POST ENQUIRY